Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07603648
Recruiting Not applicable

Immediate Electrophysiological Effects of Different Atrial Pacing Sites on P-Wave Characteristics

NCT07603648 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai Tong Ren Hospital
Phase
Not applicable
Started
2026-03-31
Last updated
2026-05-22

Condition(s) studied

Pacing TherapyCardiac Pacing

Investigational drug(s) / intervention(s)

Multi-site short-time pacing

Multi-site short-time pacing: Short-time atrial pacing at right atrial appendage (RAA), atrial septum, Bachmann's bundle (BB) area, and posterosuperior bundle (PSB) regions (high and low levels) during regular pacemaker implantation procedures are applied for acute electrocardiogram and echocardiogram testings.

Study summary

This is a prospective, single-center, non-randomized, within-subject interventional study. The purpose is to compare the immediate effects of different atrial pacing sites on atrial electrical activation, as reflected by P-wave characteristics on surface electrocardiography (ECG).

During pacemaker implantation, short-term pacing will be performed sequentially at multiple predefined atrial sites, including the right atrial appendage (RAA), atrial septum, Bachmann's bundle (BB) area, and posterosuperior bundle (PSB) regions. ECG parameters will be recorded at each site to evaluate differences in P-wave duration and morphology.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥18 years * Sinus rhythm at baseline * Indication for permanent pacemaker implantation with planned atrial lead placement * Willing and able to provide written informed consent Exclusion Criteria: * Long-standing persistent or permanent atrial fibrillation, or prior atrioventricular node ablation * Prior cardiac implantable electronic device (CIED) requiring revision, replacement, or upgrade * Indication for implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) * Significant valvular heart disease, cardiomyopathy, or prior cardiac surgery * Angina or acute myocardial infarction within 3 months before enrollment * Chronic use of antiarrhythmic drugs * Severe hepatic or renal dysfunction, or other serious systemic diseases * Participation in another clinical study that may interfere with the objectives of this study

Primary outcome measure(s)

  • Atrial-paced ECG P-wave duration — During implantation

Trial sites (2)

FacilityCityRegionStatus
Affiliated Hospital of Zunyi Medical College Zunyi Guizhou Not Yet Recruiting
Tong Ren Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai Municipality Recruiting

More Shanghai Tong Ren Hospital trials in China

Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction Recruiting
A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia Recruiting
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction Recruiting
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results Recruiting
The Prognosis Effect of Indocyanine Green (ICG) Fluorescence Guided Surgery on Disease-free Survival (DFS) of Stage III Colorectal Cancer Enrolling by invitation

Other trials for the same condition

Posterosuperior Bundle Pacing for Prevention of Atrial Fibrillation in Patients With Sinus Node Dysfunction Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07603648 on ClinicalTrials.gov ↗ ← All trials in China